Clinical decision support of therapeutic drug monitoring of phenytoin: measured versus adjusted phenytoin plasma concentrations

Matthew D Krasowski1* and Louis E Penrod2,3

Abstract

Background: Therapeutic drug monitoring of phenytoin by measurement of plasma concentrations is often employed to optimize clinical efficacy while avoiding adverse effects. This is most commonly accomplished by measurement of total phenytoin plasma concentrations. However, total phenytoin levels can be misleading in patients with factors such as low plasma albumin that alter the free (unbound) concentrations of phenytoin. Direct measurement of free phenytoin concentrations in plasma is more costly and time-consuming than determination of total phenytoin concentrations. An alternative to direct measurement of free phenytoin concentrations is use of the Sheiner-Tozer equation to calculate an adjusted phenytoin that corrects for the plasma albumin concentration. Innovative medical informatics tools to identify patients who would benefit from adjusted phenytoin calculations or from laboratory measurement of free phenytoin are needed to improve safety and efficacy of phenytoin pharmacotherapy. The electronic medical record for an academic medical center was searched for the time period from August 1, 1996 to November 30, 2010 for patients who had total phenytoin and free phenytoin determined on the same blood draw, and also a plasma albumin measurement within 7 days of the phenytoin measurements. The measured free phenytoin plasma concentration was used as the gold standard.

Results: In this study, the standard Sheiner-Tozer formula for calculating an estimated (adjusted) phenytoin level more frequently underestimates than overestimates the measured free phenytoin relative to the respective therapeutic ranges. Adjusted phenytoin concentrations provided superior classification of patients than total phenytoin measurements, particularly at low albumin concentrations. Albumin plasma concentrations up to 7 days prior to total phenytoin measurements can be used for adjusted phenytoin concentrations.

Conclusions: The results suggest that a measured free phenytoin should be obtained where possible to guide phenytoin dosing. If this is not feasible, then an adjusted phenytoin can supplement a total phenytoin concentration, particularly for patients with low plasma albumin.

Background

Recent reports by the Institute of Medicine (IOM) have publicized the risk of medical errors inherent in America’s healthcare system [1,2]. To substantially improve the quality of care, the IOM has called for computerized physician order entry (CPOE) coupled with clinical decision support systems (DSS) [2]. Such a combination has been shown to reduce medical errors [3] and speed adoption of new patterns of practice [4] as prime examples of improved quality of care. Still more recent reports indicate that the processes by which CPOE systems are implemented are the key to success or failure in reducing errors [5-7]. The same diligence in implementation and ongoing review are needed for clinical DSS to effect change positively.

A significant challenge in clinical care is administration of phenytoin (PHT) to control seizures. Drug levels that are low may not control the seizures adequately; while drug levels that are too high can result in toxic effects. PHT dosing is challenging because the drug exhibits non-linear pharmacokinetics, zero-order elimination, and a multitude of drug-drug interactions [8-11].
For this reason, drug levels are measured to optimize dosing, with the usual therapeutic range for plasma total PHT concentration (PHT\textsubscript{total}) considered to be 10-20 mg/L [12]. PHT is also highly bound to plasma proteins. It is the free, or unbound, portion of the drug that is biologically active and which causes both therapeutic and toxic effects [13]. The therapeutic range for free PHT plasma concentrations (PHT\textsubscript{free}) is generally considered to be 1-2 mg/L (i.e., PHT\textsubscript{total} divided by 10 or PHT\textsubscript{total}/10), using an estimated 10% free fraction of PHT [12].

One factor that causes significant variation in PHT plasma protein binding is a low plasma albumin level (hypoalbuminemia), leading to an increased free PHT fraction, although other factors such as uremia or drug-drug interactions (e.g., inhibition of phenytoin metabolism by valproic acid) can also alter the free fraction of PHT [14,15]. In this situation, the usual PHT\textsubscript{total} assay, which measures both bound and free portions together, may provide discrepant results relative to the PHT\textsubscript{free} concentration [8,16]. Equations to estimate an adjusted free PHT (PHT\textsubscript{adj_free}) using a PHT\textsubscript{total} value exist to better approximate dose and gauge clinical efficacy. A common method of predicting the effect of albumin plasma concentrations on PHT level is the Sheiner-Tozer equation [14,15], which can be used to calculate PHT\textsubscript{adj_free}. If a DSS using this method indicates that the PHT\textsubscript{adj_free} is outside the desired target concentration range in a given individual, then PHT dose may be adjusted by the clinician and, in addition, the clinician may decide to monitor PHT\textsubscript{free} directly. In this study, we perform a large retrospective study to determine how well the PHT\textsubscript{adj_free} concentrations compare to direct measurement of PHT\textsubscript{free}.

### Results and Discussion

There were a total of 1,753 datapoints from 756 patients that had simultaneous determination of PHT\textsubscript{total} and PHT\textsubscript{free} and also a plasma albumin measured within 7 days of the PHT measurements. As shown in Table 1, the patient population studied was mostly 15 years or older (n = 701 out of 756). Roughly equal numbers of patients were being administered monotherapy with phenytoin for seizure control (n = 386) as compared to being prescribed one or more additional anti-epileptic drugs in addition to phenytoin (n = 370). The most common co-administered anti-epileptic drugs were levetiracetam (167 patients), phenobarbital (51 patients), and valproic acid (44 patients) (Table 1). At the time of blood draw for the initial phenytoin drug level, 263 patients had documentation of seizure within 24 hrs while 493 patients did not.

Figures 1A and 1B show scatterplots of PHT\textsubscript{free} versus PHT\textsubscript{total}/10 and PHT\textsubscript{free} versus PHT\textsubscript{adj_free}, respectively, using only the initial laboratory data for patients (i.e., not including repeat measurements for patients). The Pearson coefficient for the correlations between PHT\textsubscript{total}/10 and PHT\textsubscript{free} was 0.72 and for PHT\textsubscript{free} and PHT\textsubscript{adj_free} was 0.79. The slope of the regression line for the relationship between PHT\textsubscript{free} versus PHT\textsubscript{total}/10 was statistically different than the line of identity (slope = 1) (95% confidence interval: 1.045-1.163, P < 0.05 for comparison of slope to 1). In contrast, the slope of the regression line for the relationship between PHT\textsubscript{free} versus PHT\textsubscript{adj_free} was not statistically different from 1 (95% confidence interval: 0.926-1.034). Additional file 1: Figure S1 (found in Additional file 1) shows plots similar to Figure 1A and 1B except using all laboratory data, including repeated measurements (i.e., using all 1,753 datapoints from 756 patients). These present very similar relationships to that seen in Figure 1A and 1B. Additional file 1: Figure S2 presents Bland-Altman (difference) plots of the data in Figure 1B, both by absolute (Additional file 1: Figure S2A) and percent bias (Additional file 1: Figure S2B).

### Table 1 Study population

|                | Males | Females |
|----------------|-------|---------|
| **Total**      | n = 422 | n = 334 |
| **Age**        |       |         |
| Average ± SD   | 52.4 ± 20.9 | 54.8 ± 21.8 |
| 0-12 months    | n = 12 | n = 8 |
| 1-14 years old | n = 22 | n = 13 |
| 15-30 years old| n = 33 | n = 24 |
| 31-59 years old| n = 192 | n = 142 |
| 60-79 years old| n = 138 | n = 108 |
| 80 years old or older | n = 25 | n = 39 |
| **Adult inpatient (not ICU)** | n = 287 | n = 248 |
| **Pediatric inpatient (not ICU)** | n = 19 | n = 10 |
| **ICU**        | n = 88 | n = 59 |
| **Emergency room** | n = 5 | n = 5 |
| **Primary care clinic** | n = 4 | n = 4 |
| **Outpatient clinic** | n = 15 | n = 8 |
| **Monotherapy with phenytoin** | n = 200 | n = 171 |
| **One additional anti-epileptic drugs** | n = 176 | n = 129 |
| **Two additional anti-epileptic drugs** | n = 38 | n = 29 |
| **Three or more additional anti-epileptic drugs** | n = 8 | n = 5 |
| **No seizures within 24 hrs of phenytoin drug level** | n = 265 | n = 228 |
| **Seizure(s) within 24 hrs of phenytoin drug level** | n = 157 | n = 106 |

\(a\) ICU intensive care unit

\(b\) Number of patients administered other anti-epileptic drugs: carbamazepine, 15; clonazepam, 5; diazepam, 10; felbamate, 9; lacosamide, 15; lamotrigine, 30; levetiracetam, 167; lorazepam, 56; pentobarbital, 14; phenobarbital, 51; primidone, 6; topiramate 19; valproic acid 44; zonisamide, 13
Figure 1 Correlation of total, adjusted, and free phenytoin plasma concentrations. (A) Correlation of PHT\textsubscript{free} versus PHT\textsubscript{total/10} for 756 patients is shown. For patients who had multiple phenytoin measurements, only the chronologically first set of PHT\textsubscript{free} and PHT\textsubscript{total/10} measurements is plotted. The solid line is the line of identity, and the dashed line is from linear regression: PHT\textsubscript{free} = 0.385 + 1.104 * PHT\textsubscript{total/10} ($R^2 = 0.51$). The 95% confidence intervals of the intercept is (0.355, 0.415) and for the slope is (1.045, 1.163). (B) Correlation of PHT\textsubscript{free} versus PHT\textsubscript{adj_free} is shown using same source of patient data as in (A). The dashed line is from linear regression: PHT\textsubscript{free} = 0.223 + 0.980 * PHT\textsubscript{adj_free} ($R^2 = 0.62$). The 95% confidence intervals of the intercept is (0.129, 0.317) and for the slope is (0.926, 1.034).
Although the \( \text{PHT}_{\text{adj_free}} \) provides a higher Pearson correlation to \( \text{PHT}_{\text{free}} \) than \( \text{PHT}_{\text{total}}/10 \), the question is whether a clinician is more likely to make a different decision when presented with \( \text{PHT}_{\text{adj_free}} \) as opposed to \( \text{PHT}_{\text{total}} \). This was investigated through the use of contingency tables. Three-by-three contingency tables were constructed comparing grouping of results for \( \text{PHT}_{\text{total}} \) and \( \text{PHT}_{\text{free}} \) with respect to their therapeutic ranges (10-20 mg/L for total phenytoin; 1-2 mg/L for free phenytoin). As Figure 2A and Additional file 1: Figure S3A shows, \( \text{PHT}_{\text{total}} \) frequently is in a lower category than \( \text{PHT}_{\text{free}} \) (e.g., \( \text{PHT}_{\text{total}} \) below its therapeutic range but \( \text{PHT}_{\text{free}} \) within or above its reference range), which could lead to clinical overdosing of the patient if \( \text{PHT}_{\text{total}} \) and not \( \text{PHT}_{\text{free}} \) were used as the basis to guide dosing. The converse situation (\( \text{PHT}_{\text{free}} \) in a lower category than \( \text{PHT}_{\text{total}} \)) was uncommon. Overall, \( \text{PHT}_{\text{free}} \) and \( \text{PHT}_{\text{total}} \) were concordant with respect to therapeutic category less than 50% of the time (43.1% for all data points and 46.6% when excluding repeated measurements).

On the other hand, three-by-three contingency tables showed that \( \text{PHT}_{\text{adj_free}} \) had improved concordance, relative to \( \text{PHT}_{\text{total}} \) to \( \text{PHT}_{\text{free}} \) with respect to therapeutic category (Figure 2B, Additional file 1: Figure S3B). Similar to the analysis between \( \text{PHT}_{\text{total}} \) and \( \text{PHT}_{\text{free}} \), \( \text{PHT}_{\text{adj_free}} \) was more frequently in a lower category to \( \text{PHT}_{\text{free}} \) than in a higher category. However, \( \text{PHT}_{\text{free}} \) and \( \text{PHT}_{\text{adj_free}} \) were concordant nearly 70% of the time (68.7% for all datapoints and 69.6% when excluding repeated measurements), statistically superior to \( \text{PHT}_{\text{total}} \) (Fisher’s exact test < 0.001).

The concordance data was also broken down into patients who did or did not have documented seizures within 24 hours of the blood draw for phenytoin drug level (Additional file 1: Figure S4) and those on phenytoin monotherapy for seizure therapy versus those also being treated with additional anti-epileptic drugs (Additional file 1: Figure S5). \( \text{PHT}_{\text{free}} \) and \( \text{PHT}_{\text{adj_free}} \) were concordant 73.2% for patient without recent seizures but only 56.6% for those who had seizures within 24 hours (Fisher’s exact test < 0.001). In contrast, \( \text{PHT}_{\text{free}} \) and \( \text{PHT}_{\text{adj_free}} \) were concordant 69.9% for patients on phenytoin monotherapy and 69.3% for patients on polytherapy for seizure control (Fisher’s exact test > 0.05).

We also looked at the three-by-three contingency table data to see how stable phenytoin measurements were for patients who had multiple phenytoin measurements over time. In particular, we compared how often, for a given patient, the temporally next phenytoin measurement fell in the same category in the three-by-three table as the previous set of measurements. For the data comparing \( \text{PHT}_{\text{total}} \) with \( \text{PHT}_{\text{free}} \), the next consecutive set of phenytoin measurements agreed 53.7% of the time with the previous measurements (529 out of 997 measurements). For the data comparing \( \text{PHT}_{\text{adj_free}} \) with \( \text{PHT}_{\text{free}} \), the next consecutive set of phenytoin measurements agreed 46.9% of the time with the previous measurements (468 out of 997 measurements). These data may reflect the predominantly inpatient population studied, where shifts in phenytoin dosing and also changes in other factors (e.g., concomitant) were needed for patients with unstable clinical status.

The difference between \( \text{PHT}_{\text{total}}/10 \) and \( \text{PHT}_{\text{free}} \) was also examined in relation to plasma albumin concentration (Figure 3A, Additional file 1: Figure S6A). The discrepancy between \( \text{PHT}_{\text{free}} \) and \( \text{PHT}_{\text{total}}/10 \) is most pronounced at low plasma albumin concentrations, where the ratio of \( \text{PHT}_{\text{free}} \) to \( \text{PHT}_{\text{total}} \) would be expected to be higher. However, there are clearly many examples of marked discrepancies between \( \text{PHT}_{\text{free}} \) and \( \text{PHT}_{\text{total}}/10 \) even when the plasma albumin concentrations is within the age-specific reference range. \( \text{PHT}_{\text{free}} \) is generally greater than \( \text{PHT}_{\text{total}}/10 \) throughout all ages with examples of patients showing differences of > 2 mg/L evident throughout all age groups. The slope of the regression line in Figure 3A was significantly different from 0 (i.e., null hypothesis of no relationship; 95% confidence interval: -2.37 to -1.90; \( P < 0.05 \)). In contrast, the difference between \( \text{PHT}_{\text{free}} \) and \( \text{PHT}_{\text{adj_free}} \) shows little relationship with respect to plasma albumin concentration (Figure 3B, Additional file 1: Figure S6B), with the slope of the regression line in Figure 3B showing no significant difference from 0 (95% confidence interval: -0.0649 to 0.0691).

The difference between \( \text{PHT}_{\text{total}}/10 \) and \( \text{PHT}_{\text{free}} \) was also examined in relation to patient age (Figure 4A, Additional file 1: Figure S7A), which revealed no statistically significant difference of the slope of the regression line in Figure 4A from 0 (95% confidence interval: -0.056 to 0.064). A similar finding was noted between the difference between \( \text{PHT}_{\text{free}} \) and \( \text{PHT}_{\text{adj_free}} \) (Figure 4B, Additional file 1: Figure S7B). The slope of the regression line in Figure 4B showed no statistically significant difference from 0 (95% confidence interval: -0.053 to 0.057).

A series of analyses were also done to try to understand what additional factors might influence how well \( \text{PHT}_{\text{adj_free}} \) predicts \( \text{PHT}_{\text{free}} \) using plots of the difference between \( \text{PHT}_{\text{free}} \) and \( \text{PHT}_{\text{adj_free}} \) and various independent variables (Figure 5; note that the statistical analyses in 5A–5D were four separate procedures). There is little influence of patient gender (Figure 5A) or days between albumin and \( \text{PHT}_{\text{free}}/\text{PHT}_{\text{total}} \) measurements (Figure 5B) on the difference between \( \text{PHT}_{\text{free}} \) and \( \text{PHT}_{\text{adj_free}} \). There was, however, a significant effect of patient location at time of PHT measurements (Figure 5C), with the deviation between \( \text{PHT}_{\text{free}} \) and \( \text{PHT}_{\text{adj_free}} \) highest in
Figure 2 Clinical decision using total phenytoin or adjusted phenytoin compared to measured free phenytoin. (A) The data is derived from three-by-three contingency tables comparing grouping of PHT\textsubscript{total} and PHT\textsubscript{free} into lower than therapeutic reference range (L), within therapeutic reference range (T), and higher than therapeutic reference range (H). For the three bar graphs on the left, PHT\textsubscript{total} would tend to lead to underdosing relative to PHT\textsubscript{free}. For the three bar graphs in the center, PHT\textsubscript{total} and PHT\textsubscript{free} are concordant. For the three bar graphs on the left, PHT\textsubscript{total} would tend to lead to overdosing relative to PHT\textsubscript{free}. For patients who had multiple phenytoin measurements, only the chronologically first set of concentrations available is plotted. The data is from 756 patients. (B) Similar design as in (A) except that PHT\textsubscript{adj\_free} (using the Sheiner-Tozer equation) is compared to PHT\textsubscript{free}. The data is from 756 patients.
Figure 3 Variation of total phenytoin, adjusted phenytoin, and free phenytoin with respect to plasma albumin concentration (A) Variation of the difference between PHT_{total/10} and PHT_{free} with respect to plasma albumin concentration. All data is from chronologically first phenytoin measurements in 756 patients. The dashed line is from linear regression: \([PHT_{total/10} - PHT_{free}] = -2.136 + 0.477 \times [\text{albumin concentration}] \) (\(R^2 = 0.19\)). The 95% confidence intervals of the intercept is (-2.37, -1.90) and for the slope is (0.406, 0.549). (B) Variation of the difference between PHT_{free} and PHT_{adj_free} with respect to plasma albumin concentration using same source of patient data in (A). The dashed line is from linear regression: \([PHT_{free} - PHT_{adj_free}] = 0.0838 + 0.0021*[\text{plasma albumin}] \) (\(R^2 = 0.004\)). The 95% confidence intervals of the intercept is (-0.138, 0.305) and for the slope is (-0.0649, 0.0691).
Figure 4 Variation of total phenytoin, adjusted phenytoin, and free phenytoin with respect to patient age. (A) Variation of the difference between \( \text{PHT}_{\text{total/10}} \) and \( \text{PHT}_{\text{free}} \) with respect to patient age. All data from chronologically first phenytoin measurements in 756 patients. The dashed line is from linear regression: \( [\text{PHT}_{\text{total/10}} - \text{PHT}_{\text{free}}] = -0.394 + 0.0038 \times \text{(patient age)} \) \((R^2 = 0.01)\). The 95% confidence intervals of the intercept is (-0.464, -0.372) and for the slope is (-0.056, 0.064). (B) Variation of the difference between \( \text{PHT}_{\text{free}} \) and \( \text{PHT}_{\text{adj_free}} \) with respect to patient age is shown using same source of data as in (A). The dashed line is from linear regression: \( [\text{PHT}_{\text{free}} - \text{PHT}_{\text{adj_free}}] = 0.0838 + 0.0021 \times \text{age} \) \((R^2 = 0.004)\). The 95% confidence intervals of the intercept is (-0.0072, 0.174) and for the slope is (-0.053, 0.057).
adult inpatient (non-ICU) and ICU units. In the inpatient settings, PHT_free was significantly greater than PHT_adj_free. PHT_free - PHT_adj_free did not vary significantly with the year in which the phenytoin measurements were performed (Figure 5D), suggesting that changes in clinical laboratory instrumentation and assays over the years of the retrospective analysis did not cause any changes in PHT_free, PHT_total, or plasma albumin concentrations that might systematically impact the relation of PHT_free to PHT_adj_free.

Figure 5 Variation of the difference of PHT_free and PHT_adj_free with respect to various independent variables. (A) Distribution of the difference between PHT_free and PHT_adj_free separated between males and females. Each dot represents a single timepoint of data with a total of 1,020 datapoints from male patients and 733 datapoints from female patients. The solid horizontal lines indicate the mean difference. There was no significant difference between males and females (unpaired t-test > 0.05). (B) Distribution of the difference between PHT_free and PHT_adj_free separated by the days in between the albumin and total phenytoin measurements (that allowed for PHT_adj_free calculation). Each dot represents a single timepoint of data with a total of 1,753 datapoints (SS9 datapoints for 0 days difference between albumin and PHT_total determination, 290 for 1 day difference, 215 for 2 days difference, 190 for 3 days difference, 152 for 4 days difference, 103 for 5 days difference, 112 for 6 days difference, and 132 for 7 days difference). The solid horizontal lines indicate the mean difference. There was no significant difference across days between albumin and phenytoin measurements (ANOVA P value > 0.05). (C) Distribution of the difference between PHT_free and PHT_adj_free separated into categories of patient location at time of laboratory ordering of PHT_total and PHT_free. ‘Adult inpatient’ and ‘Peds inpatient’ encompass all inpatient locations excluding intensive care units (ICUs), with adult defined as age 15 or older. ‘All other locations’ encompasses outpatient clinics, emergency room, and scheduled draws at hospital phlebotomy stations. (D) Distribution of the difference between PHT_free and PHT_adj_free separated into years in which the laboratory measurements were performed. There was a significant effect of patient location at time of PHT measurements (ANOVA P value < 0.0001).
Since its initial development, the Sheiner-Tozer equation has been widely used to assist therapeutic drug monitoring of phenytoin [14,15]. It is even included in the MedMath module of Epocrates® software (registered trademark of Epocrates, Inc., San Mateo, CA, USA). Despite this widespread use, there has been considerable controversy over whether inaccuracies in the model justify its use or not. Some authors have argued that since PHT$_{\text{free}}$ levels may not be readily available, the adjustment in cases of known hypoalbuminemia provides better guidance in dosing than the total PHT level obtained in the usual assay used for therapeutic drug monitoring [9,15,17]. In a population of “critically ill neurosurgical patients”, Mlynarek et al. concluded that the Sheiner-Tozer equation provided “an unbiased, precise clinical estimate” in cases where the PHT$_{\text{free}}$ level “is unavailable or impractical” [17]. For rural clinics in sub-Saharan Africa where malnutrition and AIDS are frequent, Fedler and Stewart concluded that the corrected value should be reported rather than the total phenytoin [9]. On the other hand, two reports from university hospital settings concluded that because of the inaccuracies of the model, the Sheiner-Tozer equation should not be used [14,18]. Other studies have recommended that PHT$_{\text{total}}$ not be used at all, and that PHT$_{\text{free}}$ alone be used for drug monitoring of PHT [19].

In our study, PHT$_{\text{adj_free}}$ provides a better estimate of PHT$_{\text{free}}$ (relative to reference range) than PHT$_{\text{total}}$. Previous studies have focused on more limited sample sizes and patient populations [14,17,18,20]. Our study included a population of mainly adults in the inpatient setting, including patients with refractory epilepsy and/or who were on multiple other anti-epileptic medications in addition to phenytoin. The linear regression lines relating PHT$_{\text{free}}$ to PHT$_{\text{adj_free}}$ have a slope close to 1 with only a slight negative bias (~0.2-0.3 mg/L) of PHT$_{\text{adj_free}}$ relative to PHT$_{\text{free}}$. However, we did demonstrate that the greatest bias between PHT$_{\text{free}}$ and PHT$_{\text{adj_free}}$ was seen in hospital inpatients, possibly due to other factors (e.g., concomitant drugs, organ failure) that can impact PHT pharmacokinetics.

In the university hospital setting, the cost to the clinical laboratory to perform the PHT$_{\text{free}}$ assay can be almost twice the cost of the PHT$_{\text{total}}$ assay. In addition, the PHT$_{\text{free}}$ assay process includes an extra ultra-filtration step that requires centrifugation [13,21]. Because of these extra steps, and for quality control, PHT$_{\text{free}}$ assays for a given day may be held and run in one or more batches during the day to limit labor-intensive steps. This contrasts with PHT$_{\text{total}}$ levels that may run throughout the day on automated instrumentation without need for separate processing steps. Thus, there may be a delay in receiving the PHT$_{\text{free}}$ results compared to the availability of the PHT$_{\text{total}}$ result on the same sample. In the case of a smaller hospital, where it may be longer until the batch of PHT$_{\text{free}}$ samples is accumulated and processed, or if PHT$_{\text{free}}$ levels are sent to a reference lab instead of done in house, the time disparity could be even greater. However, the added costs of the PHT$_{\text{free}}$ assay should be assessed in context with the risks of suboptimal phenytoin dosing (e.g., poor seizure control, toxicity, etc.).

Most of the “rule of thumb” equations in common use presume that the clinician is doing the calculation by hand or calculator, using a few readily available results to derive additional knowledge not directly reported. A modern electronic health record (EHR) with integrated DSS can provide additional value for the clinician by doing these calculations automatically and posting the results, saving time and eliminating errors in calculation. One of the authors has taken this approach at the University of Pittsburgh Medical Center (UPMC) by developing and implementing rules to provide Anion Gap, Adjusted Sodium for hyperglycemia, and Adjusted Calcium for hypoalbuminemia, in addition to an Adjusted Phenytoin Rule. In all cases, interpretive data is attached to the result to further assist the clinician in decision making. Education of clinicians is important to emphasize the difference and limitations of both calculated and directly measured parameters.

There are several main limitations to the analysis presented in this paper. First, the patient population contains far more adults than pediatric patients. Consequently, the results are mostly applicable to adult patients. Future studies targeted at children, especially very young children, are needed. Second, the majority of data points arise from patients in inpatient units (including intensive care units) with lesser availability of data points arising from patients in outpatient clinics or the emergency room. However, the sample size of this study exceeds that of previous studies and contains a patient population that likely is similar to that analyzed by clinical laboratories at many academic medical centers, and has produced results comparable to other similar studies of academic medical center patient populations [14,18]. Lastly, although nutritional status was not examined in detail, it is likely that most patients in the study were well-nourished and thus the findings are most applicable to other well-nourished populations.

Addressing the question of whether a better model than the Sheiner-Tozer equation could be implemented is the subject of additional analysis and development currently underway. The analysis reported here, along with the capabilities of the EHR and DSS, suggest additional possibilities to enhance the medical knowledge available to clinicians at the point of care. In addition to hypoalbuminemia, there are other factors that can influence binding of PHT and alter the free PHT fraction.
[14]. With a “rule of thumb” type calculation, it is prohibitive to track these additional factors and perform the calculations they would entail by hand or using a non-programmable calculator. However, given the extensive data available electronically in the EHR and the logic capabilities of a modern DSS, it may become practical to implement far more complex models than those traditionally used in clinical practice. With knowledge discovery tools, the data available in the EHR database provide a substrate for increasingly sophisticated models. The development and testing of a model that predicts free phenytoin better than done by the Sheiner-Tozer model is the focus of additional research by the authors.

Conclusions
In this study, the standard formula for calculating an estimated (adjusted) phenytoin level more frequently underestimates than overestimates the free phenytoin relative to the respective therapeutic ranges. Estimated free phenytoin concentrations predicted measured free phenytoin concentrations better than total phenytoin measurements, although there is considerable scatter in the data. The results suggest that a measured free phenytoin should be obtained where possible to guide phenytoin dosing. If this is not feasible, then an adjusted phenytoin can supplement a total phenytoin concentration, with concurrent education of physicians as to the limitations of the adjusted phenytoin prediction.

Methods
The project had Institutional Review Board approval from the University of Iowa. The electronic medical record (Epic, Epic Systems Inc., Madison, WI, USA) was searched for the time period from 8/1/1996 to 11/30/2010 for patients with PHTtotal and PHTfree determined on the same blood draw and also a plasma albumin determined within the past seven days of the phenytoin measurements, with PHTtotal, PHTfree, plasma albumin concentration, patient age, location (e.g., inpatient, outpatient, etc.) and gender downloaded. Chart review was performed to ascertain other anti-epileptic medications used in addition to phenytoin, and also whether patients had seizures within 24 hrs of the phenytoin drug level. During the entire time period of the retrospective analysis, the University of Iowa Hospitals and Clinics central clinical laboratory used the same assays to measure plasma phenytoin and free phenytoin on Roche Diagnostics (Indianapolis, IN, USA) P module automated chemistry analyzers. The total phenytoin measurement was performed using the Roche Phenytoin CEDIA (cloned enzyme donor immunoassay) method according to manufacturer’s instructions. The free phenytoin assay was the Siemens Syva Emit 2000 Phenytoin Assay, an immunoassay adapted for use on the Roche modular P analyzer [22]. Specifically, plasma specimens were first allowed to equilibrate to room temperature. Then 500 μL of sample was applied to the sample reservoir of an assembled Amicon micropartition system MPS-1 (Millipore, Billerica, MA, USA), making sure no air was trapped in the reservoir. The reservoirs were then capped and centrifuged at 3400 rpm for 20 min using a centrifuge equipped with an angle head rotor. The ultrafiltrate was then transferred to a sample cup and analyzed. The characteristics of the study population are summarized in Table 1.

The Sheiner-Tozer equation is expressed as:

\[
PHT_{adj\_free} = \frac{PHT_{total}}{(0.2 \times \text{Albumin}) + 0.1)}/10,
\]

with PHT plasma concentrations in units of mg/L and albumin plasma concentrations (Albumin) in units of g/dL. This assumes an estimated free fraction of PHT of 10%.

For comparison analysis, PHTfree was considered the reference method (comparator). Comparisons of whether PHTtotal, PHTfree and PHTadj_free results fell within the same range compared to their respective therapeutic ranges gave an indication of the accuracy of the prediction models. Chi-squared analysis of decision making and ANOVA were performed using SPSS version 13.0 (SPSS, Inc., Chicago, IL, USA). Linear regression and Pearson correlation analysis were carried out in EP Evaluator release 9 (Data Innovations, South Burlington, VT, USA). Statistical comparison of linear regression utilized two-tailed t tests in EP Evaluator.

Additional material

Additional file 1: Figure S1 (correlation of PHTfree versus PHTtotal/10 and PHTfree versus PHTadj_free), Figure S2 (Bland-Altman plots), Figure S3 (three-by-three contingency tables of PHTtotal and PHTfree), Figure S4 (three-by-three contingency tables of PHTadj_free and PHTtotal comparing those with recent seizures or no recent seizures), Figure S5 (three-by-three contingency tables of PHTadj_free and PHTfree comparing those on phenytoin monotherapy versus polytherapy with other anti-epileptic drugs), Figure S6 (effect of albumin concentration on free phenytoin estimation), and Figure S7 (effect of patient age on free phenytoin estimation).

Acknowledgements
We thank the staff of the Clinical Chemistry laboratory (particularly Jeff Kulhavy) for help in understanding laboratory practices and history of phenytoin and free phenytoin analysis. MDK thanks the Department of Pathology (Dr. Michael Cohen, Department Executive Officer) for providing research funding.

Author details
1Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA. 2Department of Physical Medicine and Rehabilitation, University of Pittsburgh, Pittsburgh, PA 15213, USA. 3Baptist Health South Florida, Miami, FL 33176, USA.
Authors’ contributions
MDK and LEP were both involved in the study concept and design, analysis and interpretation of the data. MDK drafted the manuscript. Both authors have read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 7 July 2011 Accepted: 14 February 2012 Published: 14 February 2012

References
1. Kohn LT, Corrigan J, Donaldson MS. To err is human: building a safe health system. Washington, DC: National Academy Press; 2000.
2. (U.S.) IoM. Committee on Quality of Health Care in America. Crossing the quality chasm: a new health system for the 21st century Washington, DC: National Academy Press; 2001.
3. Bates DW, Cohen M, Leape LL, Overhage JM, Shabot MM, Sheridan T: Reducing the frequency of errors in medicine using information technology. J Am Med Inform Assoc 2001, 8:299-308.
4. Teich JM, Schmiz JL, Kuperman GJ, Bates DW: Effects of computerized physician order entry on prescribing practices. Arch Intern Med 2000, 160:2741-2747.
5. Koppel R, Metlay JP, Cohen A, Abaluck B, Localio AR, Kimmel SE, Strom BL: Role of computerized physician order entry system in facilitating medication errors. JAMA 2005, 293:1197-1203.
6. Berger RG, Kischak JP: Computerized physician order entry: helpful or harmful? J Am Med Inform Assoc 2004, 11:100-103.
7. Ash JS, Berg M, Coiera E: Some unintended consequences of information technology in health care: the nature of patient care information system-related errors. J Am Med Inform Assoc 2004, 11:104-112.
8. Dasgupta A: Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. Clin Chim Acta 2007, 377:1-13.
9. Fedler C, Stewart MJ: Plasma total phenytoin: a possibly misleading test in developing countries. Ther Drug Monit 1999, 21:15-160.
10. Martin E, Tozer TN, Sheiner LB, Riegelman S: The clinical pharmacokinetics of phenytoin. J Pharmacokin Biopharm 1977, 5:579-596.
11. Perucca E: Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006, 61:246-255.
12. Paraskeos P, Michigan BFD, Cloyd JC, Glauser TA, Johannessen S, Tomson T, Perucca E: Antiepileptic drugs - best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008, 49:1239-1276.
13. Dasgupta A: Clinical utility of free drug monitoring. Clin Chem Lab Med 2002, 40:986-993.
14. Banh HL, Burton ME, Sperring MR: Intervariable and intrapatient variability in phenytoin protein binding. Ther Drug Monit 2002, 24:379-385.
15. Profeta LM, Bradbury K, Mehl B: Pharmacokinetic considerations in phenytoin pharmacotherapy: preventing overdoses and underdoses. Mt Sinai J Med 1995, 62:312-314.
16. Chan K, Beran RG: Value of therapeutic drug level monitoring and unbound (free) levels. Seizure 2008, 17:572-575.
17. Mlynarek ME, Peterson EL, Zarowitz BJ: Predicting unbound phenytoin concentrations in the critically ill neurological patient. Ann Pharmacother 1996, 30:219-223.
18. Monaghan MS, Marx MA, Olsen KM, Turner PD, Bergman KL: Correlation and prediction of phenytoin protein binding using standard laboratory parameters in patients after renal transplantation. Ther Drug Monit 2001, 23:265-267.
19. Burt MA, Anderson DC, Kloss J, Apple FS: Evidence-based implementation of free phenytoin therapeutic drug monitoring. Clin Chem 2000, 46:1132-1135.
20. Hong JM, Choi YC, Kim WJ: Differences between the measured and calculated free serum phenytoin concentrations in epileptic patients. Yonsei Med J 2009, 50:517-520.
21. McMillen GA, Juonke J, Dasgupta A: Effect of ultrafiltrate volume on determination of free phenytoin concentration. Ther Drug Monit 2005, 27:630-633.

Pre-publication history
The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1472-6947/12/7/prepub
doi:10.1186/1472-6947-12-7

Cite this article as: Krasowski and Penrod: Clinical decision support of therapeutic drug monitoring of phenytoin: measured versus adjusted phenytoin plasma concentrations. BMC Medical Informatics and Decision Making 2012 12:7.

Submit your next manuscript to BioMed Central and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit